Hong Kong Expands Medical Device Listing Scope for Injectable Dermal Fillers

On May 13, 2026, Hong Kong’s Medical Device Division (MDD) updated its guidance to include injectable dermal fillers within the scope of medical devices under the Medical Device Administrative Control System (MDACS).

The update establishes a clearer and more practical regulatory pathway for companies seeking Hong Kong market access for cosmetic injectable products, particularly dermal fillers that previously faced market uncertainty.

At a Glance: What the MDACS Update Changes

• Injectable dermal fillers are now explicitly included under MDACS scope
• Cosmetic-only indications may now be accepted
• Previously rejected products may now qualify for listing
• Classification uncertainty between pharmaceutical and device frameworks is reduced
• Full product configuration must be approved under a single legal manufacturer

Regulatory Background: A Longstanding Regulatory Grey Area

Injectable products are generally classified as pharmaceutical products under the Pharmacy and Poisons Ordinance (Cap. 138), creating challenges for companies marketing injectable aesthetic products in Hong Kong.

Many dermal fillers — particularly those intended solely for cosmetic purposes — fell into a regulatory grey area, where classification pathways were unclear and, in many cases, commercially impractical.

Key challenges included:

• Products were not accepted for MDACS listing due to lack of a recognized medical indication
• Pharmaceutical registration was often not feasible due to positioning, data, or regulatory strategy

As a result, market access for injectable aesthetic products was uncertain, with heightened risks of customs delays, non-clearance, and regulatory rejection.

What the Updated GN-00 Guidance Clarifies

Hong Kong’s regulatory framework for injectable dermal fillers shifted significantly with the May 13, 2026 update to the Guidance Notes for Definitions and Abbreviations for Medical Device Administrative Control System (GN-00). The new approach took effect immediately, applying to all medical device listing considerations under MDACS.

Key regulatory milestones leading to this shift include:

• April 23, 2026 — The Hong Kong Pharmacy and Poisons Board updates classification guidance for pharmaceutical products
• May 13, 2026 — The MDD formally includes injectable dermal fillers under MDACS

The updated GN-00 guidance clarifies that:

• Injectable dermal fillers, including hyaluronic acid-based products, are considered medical devices under MDACS
• This includes fillers for mucous membranes and aesthetic applications
• Products may be accepted even if intended purely for cosmetic use, subject to regulatory assessment

This represents a significant policy shift from previous practice, where cosmetic-only injectables were typically excluded from the scope for listing under the MDACS.

Key Considerations for Manufacturers and Market Applicants

With the updated GN-00 guidance now in effect, companies planning to enter or expand in the Hong Kong market should take a strategic approach. The update not only clarifies the regulatory pathway for injectable dermal fillers but also creates opportunities to revisit previously challenging products and optimize product configurations.

To make the most of this regulatory shift, manufacturers and market applicants should consider the following actions:

1. Reassess Previously Non-Viable Products

Products previously excluded due to cosmetic-only indications should be re-evaluated under the new MDACS framework, potentially unlocking market opportunities that were once inaccessible.

2. Review Product Configuration and Manufacturer Structure

The entire product configuration (filler, syringe, and needle) should be covered under a single overseas reference approval held by one legal manufacturer.

3. Reconsider Classification Strategy

The update provides a viable alternative to pharmaceutical registration, particularly for dermal fillers that previously faced regulatory barriers.

4. Monitor Regulatory Alignment Trends

Hong Kong continues to align more closely with international regulatory frameworks (EU, Mainland China, US), where dermal fillers are typically regulated as medical devices. Awareness of these trends can help inform regulatory and strategic planning.

5. Leverage MDACS for Early Market Entry

Although voluntary, MDACS listing enhances market credibility, supports distributor engagement, and positions products for smoother future transition to mandatory registration. Companies pursuing listing can benefit from partnering with experienced regulatory advisors, such as Cisema, to ensure compliance and streamline market entry.

Final Thoughts: A More Defined Pathway for Dermal Fillers in Hong Kong

The GN-00 update marks a turning point for injectable dermal fillers in Hong Kong, transforming a previously restrictive regulatory environment into a more accessible and predictable pathway.

This creates a timely opportunity for medical aesthetics companies to enter or re-enter the Hong Kong market through MDACS listing, provided that regulatory expectations are properly addressed.

Companies that act early can secure a strategic advantage by aligning classification, documentation, and manufacturing structure with the updated framework. Cisema supports clients in navigating these changes, minimizing regulatory risk, and accelerating compliant market entry.

Contact Cisema today to assess how this update impacts your product portfolio and market entry plans.

Further Information

Explore Cisema’s Hong Kong MDACS Listing Support Services.

References

• HKMDD - Guidance Notes "[GN-00]Guidance Notes for Definitions and Abbreviations for Medical DeviceAdministrative Control System" has been updated
• PPBHK - Guidance on the Classification of Products as “Pharmaceutical Products” under the Pharmacy andPoisons Ordinance (Cap. 138) and Issues Relating to the Classification ofInjectable Dermal Fillers (Chinese only)